{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:23:16Z","timestamp":1786980196352,"version":"build-2736575974"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T00:00:00Z","timestamp":1646265600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T00:00:00Z","timestamp":1646265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>One of the most critical issues in the management of Hodgkin lymphoma (HL) patients who resulted as primary relapsed or refractory is to obtain a minimal disease status before autologous stem cell transplantation (ASCT). Finding a salvage regimen able to induce this status without severe toxicity would represent a major achievement in this setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A single\u2010center retrospective study was conducted to assess effectiveness and safety of BEGEV (bendamustine, gemcitabine, and vinorelbine) regimen as first salvage setting prior to ASCT in HL patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Forty-three patients were treated in our institution between October 2017 and November 2020. Median age at BEGEV therapy was 35.0\u00a0years (range 17.2\u2013\u200970.0), and the median time from frontline therapy to the first cycle of BEGEV was 79.5\u00a0days (range 4\u20132267). At the end of treatment, 31 patients achieved a complete response (CR), with an overall response rate of 76.7%. Forty-one patients harvested CD34+ cells and 35\/43 (81.4%) patients underwent ASCT. With a median follow\u2010up of 22\u00a0months, 4 CR patients had disease relapse, yielding an estimated disease-free survival of 73.9% at 34\u00a0months. The estimated 2\u2010year progression-free survival was 66.7%. Response to first-line chemotherapy did not significantly influence prognosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>BEGEV regimen was well tolerated, and reversible haematological toxic effects were the most common adverse events. Real-life data on BEGEV regimen as first salvage setting showed a relevant rate of objective responses and a limited myelotoxicity with no impairment of a subsequent mobilization of peripheral blood stem cells.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00432-022-03955-w","type":"journal-article","created":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T11:02:54Z","timestamp":1646305374000},"page":"1043-1047","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["BEGEV salvage regimen in relapsed\/refractory classical Hodgkin lymphoma: a real-life experience"],"prefix":"10.1007","volume":"149","author":[{"given":"Vittorio","family":"Stefoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Argnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Carella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Casadei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Morigi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ginevra","family":"Lolli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Broccoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"Pellegrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Nanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo Elia","family":"Coppola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2112-2651","authenticated-orcid":false,"given":"Pier Luigi","family":"Zinzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,3]]},"reference":[{"key":"3955_CR1","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.3109\/10428194.2013.798868","volume":"54","author":"S Arai","year":"2013","unstructured":"Arai S, Fanale M, DeVos S, Engert A et al (2013) Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant. Leuk Lymphoma 54:2531\u20132533. https:\/\/doi.org\/10.3109\/10428194.2013.798868","journal-title":"Leuk Lymphoma"},{"key":"3955_CR2","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1093\/annonc\/mdg496","volume":"14","author":"T Baetz","year":"2003","unstructured":"Baetz T, Belch A, Couban S et al (2003) Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin\u2019s disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 14:1762\u20131767. https:\/\/doi.org\/10.1093\/annonc\/mdg496","journal-title":"Ann Oncol"},{"key":"3955_CR3","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/bjh.15639","volume":"184","author":"A Broccoli","year":"2019","unstructured":"Broccoli A, Zinzani PL (2019) The role of transplantation in Hodgkin lymphoma. Br J Haematol 184:93\u2013104. https:\/\/doi.org\/10.1111\/bjh.15639","journal-title":"Br J Haematol"},{"key":"3955_CR4","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.3324\/haematol.2011.056051","volume":"97","author":"R Devillier","year":"2012","unstructured":"Devillier R, Coso D, Castagna L et al (2012) Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and\/or refractory Hodgkin\u2019s lymphoma responding to prior salvage therapy. Haematologica 97:1073\u20131079. https:\/\/doi.org\/10.3324\/haematol.2011.056051","journal-title":"Haematologica"},{"key":"3955_CR5","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1111\/bjh.12824","volume":"165","author":"RD Gentzler","year":"2014","unstructured":"Gentzler RD, Evens AM, Rademaker AW et al (2014) F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphoma. Br J Haematol 165:793\u2013800. https:\/\/doi.org\/10.1111\/bjh.12824","journal-title":"Br J Haematol"},{"key":"3955_CR6","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1093\/annonc\/mdf221","volume":"13","author":"A Josting","year":"2002","unstructured":"Josting A, Rudolph C, Reiser M et al (2002) Time-intensified dexamethasone\/cisplatin\/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin\u2019s disease. Ann Oncol 13:1628\u20131635. https:\/\/doi.org\/10.1093\/annonc\/mdf221","journal-title":"Ann Oncol"},{"key":"3955_CR7","doi-asserted-by":"publisher","first-page":"5074","DOI":"10.1200\/JCO.2010.30.5771","volume":"28","author":"A Josting","year":"2010","unstructured":"Josting A, M\u00fcller H, Borchmann P et al (2010) Dose intensity of chemotherapy in patients with relapsed Hodgkin\u2019s lymphoma. J Clin Oncol 28:5074\u20135080. https:\/\/doi.org\/10.1200\/JCO.2010.30.5771","journal-title":"J Clin Oncol"},{"key":"3955_CR8","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-l","volume":"341","author":"DC Linch","year":"1993","unstructured":"Linch DC, Winfield D, Goldstone AH et al (1993) Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin\u2019 disease: results of a BNLI randomised trial. Lancet 341:1051\u20131054. https:\/\/doi.org\/10.1016\/0140-6736(93)92411-l","journal-title":"Lancet"},{"key":"3955_CR9","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1182\/blood.v97.3.616","volume":"97","author":"CH Moskowitz","year":"2001","unstructured":"Moskowitz CH, Nimer SD, Zelenetz AD et al (2001) A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 97:616\u2013623. https:\/\/doi.org\/10.1182\/blood.v97.3.616","journal-title":"Blood"},{"key":"3955_CR10","doi-asserted-by":"publisher","first-page":"4934","DOI":"10.1182\/blood-2010-05-282756","volume":"116","author":"AJ Moskowitz","year":"2010","unstructured":"Moskowitz AJ, Yahalom J, Kewalramani T et al (2010a) Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Blood 116:4934\u20134937. https:\/\/doi.org\/10.1182\/blood-2010-05-282756","journal-title":"Blood"},{"key":"3955_CR11","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1111\/j.1365-2141.2009.08037.x","volume":"148","author":"CH Moskowitz","year":"2010","unstructured":"Moskowitz CH, Yahalom J, Zelenetz AD et al (2010b) High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging. Br J Haematol 148:890\u2013897. https:\/\/doi.org\/10.1111\/j.1365-2141.2009.08037.x","journal-title":"Br J Haematol"},{"key":"3955_CR12","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3324\/haematol.10661","volume":"92","author":"A Santoro","year":"2007","unstructured":"Santoro A, Magagnoli M, Spina M et al (2007) Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin\u2019s lymphoma. Haematologica 92:35\u201341. https:\/\/doi.org\/10.3324\/haematol.10661","journal-title":"Haematologica"},{"key":"3955_CR13","doi-asserted-by":"publisher","first-page":"3293","DOI":"10.1200\/JCO.2016.66.4466","volume":"34","author":"A Santoro","year":"2016","unstructured":"Santoro A, Mazza R, Pulsoni A et al (2016) Bendamustine in combination with gemcitabine and vinorelbine is an effective regimen as induction chemotherapy before autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma: final results of a multicenter phase II study. J Clin Oncol 34:3293\u20133299. https:\/\/doi.org\/10.1200\/JCO.2016.66.4466","journal-title":"J Clin Oncol"},{"key":"3955_CR14","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1182\/bloodadvances.2019000984","volume":"4","author":"A Santoro","year":"2020","unstructured":"Santoro A, Mazza R, Pulsoni A et al (2020) Five-year results of the BEGEV salvage regimen in relapsed\/refractory classical Hodgkin lymphoma. Blood Adv 4:136\u2013140. https:\/\/doi.org\/10.1182\/bloodadvances.2019000984","journal-title":"Blood Adv"},{"key":"3955_CR15","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","volume":"359","author":"N Schmitz","year":"2002","unstructured":"Schmitz N, Pfistner B, Sextro M et al (2002) Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin\u2019s disease: a randomised trial. Lancet 359:2065\u20132071. https:\/\/doi.org\/10.1016\/S0140-6736(02)08938-9","journal-title":"Lancet"},{"key":"3955_CR16","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1093\/annonc\/mdi119","volume":"16","author":"A Sureda","year":"2005","unstructured":"Sureda A, Constans M, Iriondo A et al (2005) Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin\u2019s lymphoma autografted after a first relapse. Ann Oncol 16:625\u2013633. https:\/\/doi.org\/10.1093\/annonc\/mdi119","journal-title":"Ann Oncol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-03955-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-022-03955-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-03955-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T05:10:13Z","timestamp":1677820213000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-022-03955-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,3]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["3955"],"URL":"https:\/\/doi.org\/10.1007\/s00432-022-03955-w","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,3]]},"assertion":[{"value":"17 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}